STAT3 and Its Pathways' Dysregulation-Underestimated Role in Urological Tumors

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Oct 14

PMID 36230984

Authors

Maciej Golus

Piotr Bugajski

Joanna Chorbinska

Wojciech Krajewski

Artur Leminski

Jolanta Saczko

Julita Kulbacka

Tomasz Szydelko

Bartosz Malkiewicz

Affiliations

Soon will be listed here.

Abstract

Nowadays, molecular research is essential for the better understanding of tumor cells' pathophysiology. The increasing number of neoplasms is taken under 'the molecular magnifying glass'; therefore, it is possible to discover the complex relationships between cytophysiology and tumor cells. Signal transducer and activator of transcription 3 (STAT3) belongs to the family of latent cytoplasmic transcription factors called STATs, which comprises seven members: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. Those proteins play important role in cytokine-activated gene expression by transducing signals from the cell membrane to the nucleus. Abnormal prolonged activation results in tumorigenesis, metastasis, cell proliferation, invasion, migration, and angiogenesis. Inhibition of this transcription factor inhibits the previously mentioned effects in cancer cells, whereas normal cells are not affected. Hence, STAT3 might be a viable target for cancer therapy.

Citing Articles

Cell-autonomous IL6ST activation suppresses prostate cancer development via STAT3/ARF/p53-driven senescence and confers an immune-active tumor microenvironment.

Sternberg C, Raigel M, Limberger T, Trachtova K, Schlederer M, Lindner D Mol Cancer. 2024; 23(1):245.

PMID: 39482716 PMC: 11526557. DOI: 10.1186/s12943-024-02114-8.

Exploring the therapeutic mechanism of Yuebi decoction on nephrotic syndrome based on network pharmacology and experimental study.

Yao T, Wang Q, Han S, Xu Y, Chen M, Wang Y Aging (Albany NY). 2024; 16(18):12623-12650.

PMID: 39311772 PMC: 11466484. DOI: 10.18632/aging.206116.

NUSAP1 Promotes Immunity and Apoptosis by the SHCBP1/JAK2/STAT3 Phosphorylation Pathway to Induce Dendritic Cell Generation in Hepatocellular Carcinoma.

Chen G, Li W, Ge R, Guo T, Zhang Y, Zhou C J Immunother. 2024; 48(2):46-57.

PMID: 38980111 PMC: 11753460. DOI: 10.1097/CJI.0000000000000531.

ITM2A inhibits the progression of bladder cancer by downregulating the phosphorylation of STAT3.

Jiang J, Xu J, Ou L, Yin C, Wang Y, Shi B Am J Cancer Res. 2024; 14(5):2202-2215.

PMID: 38859860 PMC: 11162684. DOI: 10.62347/KHCC9690.

Current and Emerging Strategies to Treat Urothelial Carcinoma.

Rani B, Ignatz-Hoover J, Rana P, Driscoll J Cancers (Basel). 2023; 15(19).

PMID: 37835580 PMC: 10571746. DOI: 10.3390/cancers15194886.

References

Jung Y, Ko J, Um J, Chinnathambi A, Alharbi S, Sethi G . LDL cholesterol promotes the proliferation of prostate and pancreatic cancer cells by activating the STAT3 pathway. J Cell Physiol. 2020; 236(7):5253-5264. DOI: 10.1002/jcp.30229. View

Sun S, Zhao Y, Li S, Qiang J, Ji Y . Anti-Tumor Effects of Astaxanthin by Inhibition of the Expression of STAT3 in Prostate Cancer. Mar Drugs. 2020; 18(8). PMC: 7459748. DOI: 10.3390/md18080415. View

Corsi F, Capradossi F, Pelliccia A, Briganti S, Bruni E, Traversa E . Apoptosis as Driver of Therapy-Induced Cancer Repopulation and Acquired Cell-Resistance (CRAC): A Simple In Vitro Model of Phoenix Rising in Prostate Cancer. Int J Mol Sci. 2022; 23(3). PMC: 8834753. DOI: 10.3390/ijms23031152. View

Huang W, Yang S, Wu C, Chen W, Huang Y, Su Y . Expression of signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 in urothelial carcinoma. Kaohsiung J Med Sci. 2009; 25(12):640-6. DOI: 10.1016/S1607-551X(09)70569-8. View

Lin W, Luo J, Sun Y, Lin C, Li G, Niu Y . ASC-J9 suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3. Cancer Lett. 2018; 425:21-30. DOI: 10.1016/j.canlet.2018.02.007. View

Mo M, Tong S, Yin H, Jin Z, Zu X, Hu X . SHCBP1 regulates STAT3/c-Myc signaling activation to promote tumor progression in penile cancer. Am J Cancer Res. 2020; 10(10):3138-3156. PMC: 7642648. View

Benerini Gatta L, Melocchi L, Bugatti M, Missale F, Lonardi S, Zanetti B . Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome. Cancers (Basel). 2019; 11(9). PMC: 6770563. DOI: 10.3390/cancers11091219. View

Canesin G, Maggio V, Palominos M, Stiehm A, Contreras H, Castellon E . STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population. Sci Rep. 2020; 10(1):13958. PMC: 7434889. DOI: 10.1038/s41598-020-70948-5. View

Ge Q, Lu M, Ju L, Qian K, Wang G, Wu C . miR-4324-RACGAP1-STAT3-ESR1 feedback loop inhibits proliferation and metastasis of bladder cancer. Int J Cancer. 2018; 144(12):3043-3055. DOI: 10.1002/ijc.32036. View

10.

Zhang W, Zhang J, Zhang Z, Guo Y, Wu Y, Wang R . Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer. Transl Oncol. 2018; 12(3):485-492. PMC: 6307990. DOI: 10.1016/j.tranon.2018.11.012. View

11.

Torbrand C, Wigertz A, Drevin L, Folkvaljon Y, Lambe M, Hakansson U . Socioeconomic factors and penile cancer risk and mortality; a population-based study. BJU Int. 2016; 119(2):254-260. DOI: 10.1111/bju.13534. View

12.

Rui X, Pan H, Shao S, Xu X . Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway. BMC Complement Altern Med. 2017; 17(1):378. PMC: 5540291. DOI: 10.1186/s12906-017-1885-y. View

13.

Xing Z, Li S, Liu Z, Zhang C, Meng M, Bai Z . The long non-coding RNA LINC00473 contributes to cell proliferation via JAK-STAT3 signaling pathway by regulating miR-195-5p/SEPT2 axis in prostate cancer. Biosci Rep. 2020; 40(9). PMC: 7494984. DOI: 10.1042/BSR20191850. View

14.

Tian P, Wei J, Li J, Ren J, Yang J . LncRNA SNHG1 regulates immune escape of renal cell carcinoma by targeting miR-129-3p to activate STAT3 and PD-L1. Cell Biol Int. 2021; 45(7):1546-1560. DOI: 10.1002/cbin.11595. View

15.

Kim Y, Yoon Y, Lee Y, Kim C, Lee S, Choung D . Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells. Bioorg Med Chem Lett. 2018; 28(14):2566-2572. DOI: 10.1016/j.bmcl.2018.05.025. View

16.

Guo Y, Zang Y, Lv L, Cai F, Qian T, Zhang G . IL‑8 promotes proliferation and inhibition of apoptosis via STAT3/AKT/NF‑κB pathway in prostate cancer. Mol Med Rep. 2017; 16(6):9035-9042. DOI: 10.3892/mmr.2017.7747. View

17.

Pencik J, Schlederer M, Gruber W, Unger C, Walker S, Chalaris A . STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat Commun. 2015; 6:7736. PMC: 4525303. DOI: 10.1038/ncomms8736. View

18.

Mo M, Tong S, Li T, Zu X, Hu X . Serum CXCL13 Level is Associated with Tumor Progression and Unfavorable Prognosis in Penile Cancer. Onco Targets Ther. 2020; 13:8757-8769. PMC: 7473990. DOI: 10.2147/OTT.S263980. View

19.

Wang B, Zhou Y, Zhang J, Jin X, Wu H, Huang H . Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Theranostics. 2020; 10(3):1033-1045. PMC: 6956820. DOI: 10.7150/thno.38137. View

20.

Zheng T, Ma G, Tang M, Li Z, Xu R . IL-8 Secreted from M2 Macrophages Promoted Prostate Tumorigenesis via STAT3/MALAT1 Pathway. Int J Mol Sci. 2018; 20(1). PMC: 6337597. DOI: 10.3390/ijms20010098. View